KOVALTRY
BAYER
Identification
- Active ingredient (INN)
- OCTOCOG ALFA (FACTEUR HUMAIN VIII ANTI HEMOPHILIQUE)
- Internal code
- 12 J 044
- Country of Origin
- Germany
- Pharmaceutical form
- Powder for Injectable Sol.
- Prescription List
- Highly Regulated (List I)
- Packaging
- 1 flc/10 ml et 1 sering 2.5ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells.
Indications
The human recombinant antihemophilic factor is indicated for use in adults and children with hemophilia A for the control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes. 2,
Pharmacodynamics
Antihemophilic Factor binds factor
IXa along with calcium and phospholipid, This complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of Action
Coagulation factor X Activator Coagulation factor IX Cofactor von Willebrand factor Binder + 5 more targets.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.